StreetAlpha.app
Home › Stocks › FTH

Faeth Therapeutics, Inc. (FTH)

Healthcare
$7.88
▼ −9.32%
LAST CLOSE · NOV 20

Faeth Therapeutics is a Texas biotech developing PIKTOR, an experimental cancer drug that blocks several points in a growth pathway. It last closed at $7.88 on Nov 20, down 9.32% on the day. The next earnings report for FTH is expected around Mon, Mar 29, 2027. For the quarter ended Sep 2026, FTH reported EPS of -$0.79. Over its last 6 reports the stock moved an average of 6.2% the session after earnings. Over the last 12 months FTH insiders bought $2.5M of stock on the open market and sold $2.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is FTH in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold FTH.

Key Stats

Last 12 months
Results
Net income
−$211.4M
EPS (diluted)
−$22.50
Free cash flow
−$43.3M
Valuation
Market cap
$203.7M
25.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$14.2M
At Sep 30
Shareholder equity
$161.1M
Shares outstanding
25.8M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$36.8M−$36.8MFY2021FY2022: −$48.6M−$48.6MFY2022FY2023: −$34.1M−$34.1MFY2023FY2024: −$30.2M−$30.2MFY2024FY2025: −$21.1M−$21.1MFY2025

From FTH's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Mar 29
Estimated date · Time not announced
Reported EPS
-$0.79
Quarter ended Sep 2026
Year ago EPS
-$3.62
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$6.17Dec '24Mar 2025: -$5.45Mar '25Jun 2025: -$3.91Jun '25Sep 2025: -$3.62Sep '25Dec 2025: -$3.74Dec '25Mar 2026: -$131.45Mar '26Jun 2026: -$2.84Jun '26Sep 2026: -$0.79Sep '26Latest -$0.79
Revenue by quarter
Not enough quarters on file yet.
How FTH moved after its last 6 reports
Average move the session after a report ±6.2%
Nov 3, 2026Time not announced+2.2%
Aug 4, 2026Time not announced−6.7%
May 15, 2026Time not announced+3.1%
Mar 30, 2026Time not announced−9.2%
Nov 14, 2025Time not announced−11.3%
Aug 5, 2025Time not announced−4.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on FTHStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on FTH
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on FTH

Technical Analysis

FTH · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 88% below its 20 day and 180% below its 50 day average. It is 223% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the 52 week low at $7.45, and the nearest resistance the Pivot at $8.28.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 26.6%/day
Key levels
$42.1452 week high+434.8%
$26.55100 day average+236.9%
$25.42200 day average+222.6%
$22.1050 day average+180.5%
$20.98Swing high (Oct 28)+166.2%
$14.8320 day average+88.2%
$8.73Pivot R1+10.8%
$8.28Pivot+5.1%
$7.88Last close
$7.4552 week low−5.5%
$7.44Pivot S1−5.6%
Indicators
RSI (14)22.96Oversold below 30Oversold
MACD-3.96Below its signal lineBearish
Stochastic0.8Near the bottom of its rangeOversold
ADX (14)36.7Trending down
Williams %R-99.7Oversold below −80, overbought above −20Oversold
CCI (20)-102.3Oversold below −100, overbought above 100Oversold
Rate of change−64.3%Change over 10 sessionsBearish
ATR (14)$2.09Typical daily range, 26.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for FTH

What happened before

See how FTH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow FTH usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How FTH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for FTHHow many large options trades hit FTH, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

FTH Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲63 buying vs 15 selling
  • ▲Held by funds +21.5 pts
  • ▲Funds holding +34
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7945+75.6%
In funds' top 1021+100.0%
Held by funds75.9%54.5%+21.5 pts
New / increased41 / 2222 / 17+61.5%
Reduced / sold out8 / 72 / 7+66.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See FTH institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

FTH Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$2.5M7 buys · 3 insiders
Sold$2.3M9 sales · 3 insiders
Cluster buy: 2 insiders bought $1.2M between Jun 22 and Jul 1.
2025-12 sold $575K2026-03 bought $818K2026-03 sold $89K2026-04 bought $523K2026-04 sold $615K2026-06 bought $863K2026-06 sold $1.0M2026-07 bought $326KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jul 1Brian C StephensonCFOBuy13,634$23.92$326K
Jun 26Brian C StephensonCFOBuy15,641$25.65$401K
Jun 23Brian C StephensonCFOBuy17,413$23.31$406K
Jun 22Anand Kiran ParikhPresident and CEOBuy2,806$19.76$55K
Jun 1James Peyer10% ownerSale25,000$20.02$501K
Jun 1Cambrian BioPharma Inc10% ownerSale25,000$20.02$501K
Every insider buy and sale for FTH over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See FTH insider trades →

From SEC Form 4 filings by FTH's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FTH is in one of them and how their past FTH trades turned out.

FTH in the AI portfolios
Loading…

FTH News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered FTH in an article yet. Here's the latest on the wider market.

FTH in the news

About Faeth Therapeutics

Faeth Therapeutics is a biotechnology company based in Austin, Texas, that develops cancer treatments. Its lead candidate, PIKTOR, is an oral combination of two drugs designed to block several points in a cell signaling pathway that drives the growth of many solid tumors. PIKTOR is being studied in endometrial cancer and breast cancer, and the company's products are still in clinical trials. The company aims its work at patients with these cancers, based on the idea that blocking more than one point in the pathway may work better than blocking a single point.

Headquarters
Austin, TX